Search Results - "Gottlieb, R.L."

Donor-Derived Transmission of Hepatitis C in a Hepatitis C-Naïve Heart Transplant Recipient Treated with a Pan-Genotypic Agent: Viral Kinetics and Implications for Expanded Donor Availability by Sam, T, Wada, S, Joseph, S.M, Trotter, J.F, Asrani, S.K, Lima, B, Gonzalez-Stawinski, G, Hall, S.A, Gottlieb, R.L

Get full text

(798) - Salvage Therapy with IVIG for Parainfluenza-3 Viral Pneumonia, Acute Respiratory Distress Syndrome, and Multiorgan Dysfunction in a Heart Transplant Recipient by Al-Abboud, O., Spak, C.W., Hall, S., Montealegre, R., Afzal, A., Gottlieb, R.L.

Get full text

Demographic Bias in Referral and Evaluation for Advanced Cardiac Therapies by van Zyl, J.S., Jamil, A.K., Felius, J., Gottlieb, R.L.

“…Cardiovascular disease is the leading cause of death for women in the US. However, 80% of ventricular assist devices (VADs) are implanted in men suggesting…”
Get full text

Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis by Maurer, Mathew S., Kale, Parag, Fontana, Marianna, Berk, John L., Grogan, Martha, Gustafsson, Finn, Hung, Rebecca R., Gottlieb, Robert L., Damy, Thibaud, González-Duarte, Alejandra, Sarswat, Nitasha, Sekijima, Yoshiki, Tahara, Nobuhiro, Taylor, Mark S., Kubanek, Milos, Donal, Erwan, Palecek, Tomas, Tsujita, Kenichi, Tang, W.H. Wilson, Yu, Wen-Chung, Obici, Laura, Simões, Marcus, Fernandes, Fábio, Poulsen, Steen Hvitfeldt, Diemberger, Igor, Perfetto, Federico, Solomon, Scott D., Di Carli, Marcelo, Badri, Prajakta, White, Matthew T., Chen, Jihong, Yureneva, Elena, Sweetser, Marianne T., Jay, Patrick Y., Garg, Pushkal P., Vest, John, Gillmore, Julian D.

“…This phase 3 trial of patisiran, a small interfering RNA that targets hepatic production of the transthyretin protein, showed efficacy in treating…”
Get full text

Associations of Perioperative, Donor, and Recipient Factors with Functional Exercise Capacity after Orthotopic Heart Transplantation by Brown, K.D., van Zyl, J.S., Cooper, C., Arce-Esquivel, A.A., Felius, J., Adams, J., Gottlieb, R.L.

“…Low functional exercise capacity (FEC) is directly associated with reduced quality of life and poor prognosis after orthotopic heart transplant (OHT). Due to…”
Get full text

Impact of Ischemic Time on Cardiopulmonary Exercise Outcomes after Orthotopic Heart Transplantation by Brown, K.D., van Zyl, J.S., Cooper, C., Felius, J., Arce-Esquivel, A.A., Adams, J., Gottlieb, R.L.

“…New donor organ allocation systems can potentially result in longer ischemic times (IT). The purpose of this study was to evaluate the effects of longer donor…”
Get full text

Absence of Pre-Transplant Pulmonary Features of Sarcoidosis is of Low Negative Predictive Value in End-Stage Cardiac Sarcoidosis by Rokadia, H.K., Jamil, A.K., Tomi, R. El, Zafar, H., Nisar, T., Petrozzi, M., Gottlieb, R.L.

“…Cardiac sarcoidosis is a potentially reversible etiology of heart failure if identified and managed in a timely fashion. Given the multisystem nature of the…”
Get full text

Safety and Efficacy of Extended-Release Tacrolimus in De Novo Heart Transplant Recipients: Preliminary Results from a Phase-II Trial by Martits-Chalangari, K., Sam, T., Guerrero-Miranda, C.Y., Kale, P., Clark, D.M., Doss, A., Flores, V.L., Zafar, H., Felius, J., Gottlieb, R.L., Hall, S.A.

“…Medication non-compliance after cardiac transplantation may be improved by simplifying dosing frequency to once-a-day extended-release tacrolimus, potentially…”
Get full text

Impact of Ischemic Time on Functional Exercise Capacity after Orthotopic Heart Transplantation by Brown, K.D., Cooper, C., Arce-Esquivel, A.A., Gottlieb, R.L., Adams, J.

“…Ischemic time (IT) is an independent risk factor for patients’ functional exercise capacity (FEC) during the months following orthotopic heart transplantation…”
Get full text

Principaux résultats d’APOLLO-B, une étude de phase 3 du patisiran chez des patients atteints d’amylose à transthyrétine avec cardiomyopathie by Maurer, M.S., Fontana, M., Berk, J.L., Gustafsson, F., Simões, M., Grogan, M., Fernandes, F., Gottlieb, R.L., Kubanek, M., Poulsen, S., Damy, T., Diemberger, I., Tahara, N., Yu, W.C., Tang, W.W., Obici, L., González-Duarte, A., Yoshiki, S., Lainé, A.F., Gillmore, J.D.

“…L’amylose à transthyrétine (ATTR) est une maladie d’évolution rapide, invalidante et mortelle. Les options thérapeutiques pour les patients atteints d’amylose…”
Get full text

Mutational analysis of the interaction between the bovine papillomavirus E5 transforming protein and the endogenous beta receptor for platelet-derived growth factor in mouse C127 cells by Nilson, L.A. (Princeton University, Princeton, NJ.), Gottlieb, R.L, Polack, G.W, DiMaio, D

“…The bovine papillomavirus E5 protein is a 44-amino-acid membrane-associated protein that forms a stable complex with the endogenous platelet-derived growth…”
Get full text